STOCK TITAN

Arvinas - ARVN STOCK NEWS

Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.

Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical leader pioneering targeted protein degradation through its PROTAC® technology. This news hub provides investors and researchers with essential updates on therapeutic developments, strategic collaborations, and clinical milestones.

Access authoritative reporting on ARVN's oncology and neurodegenerative disease programs, including estrogen receptor degraders for breast cancer and novel neurological candidates. Our curated news collection features:

• Clinical trial developments
• Research collaborations
• Regulatory milestones
• Scientific presentations

Bookmark this page for real-time updates on ARVN's progress in addressing previously undruggable targets through innovative protein degradation approaches. Verify information directly through official company communications and SEC filings.

Rhea-AI Summary

Arvinas (NASDAQ: ARVN) announced that results from its Phase 3 VERITAC-2 clinical trial will be presented as a late-breaking oral presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will reveal the first pivotal data for vepdegestrant, a potential first-in-class oral PROTAC estrogen receptor degrader, being developed jointly with Pfizer.

The trial evaluated vepdegestrant versus fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The presentation, scheduled for May 31, 2025, will be delivered by Dr. Erika P. Hamilton from the Sarah Cannon Research Institute's Breast Cancer Research Program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary

Arvinas (NASDAQ: ARVN) announced it will present new preclinical combination data for ARV-393, their investigational PROTAC BCL6 degrader, at the upcoming AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation will focus on ARV-393's potential combination with standard lymphoma treatments.

The research highlights ARV-393, a PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), which is a transcriptional repressor and major driver of B-cell lymphomas. The poster presentation, titled 'ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models,' will be presented on April 28, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences clinical trial
-
Rhea-AI Summary

Arvinas (ARVN) presented promising first-in-human clinical trial data for ARV-102, their investigational oral PROTAC LRRK2 degrader, at AD/PD™ 2025. The trial demonstrated that ARV-102 successfully penetrates the blood-brain barrier and achieves substantial LRRK2 protein degradation in both central and peripheral systems.

Key findings showed ARV-102 was well-tolerated with no serious adverse events. At single doses ≥60mg and daily doses ≥20mg, the drug achieved >50% LRRK2 reduction in cerebrospinal fluid and >90% reduction in peripheral blood mononuclear cells. The Phase 1 trial included single ascending dose (SAD) cohorts (10-200mg) and multiple ascending dose (MAD) cohorts (10-80mg).

The company has initiated a Phase 1 trial in Parkinson's disease patients and expects to complete enrollment and present initial data from the SAD cohort, as well as initiate the MAD cohort, in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
Rhea-AI Summary

Arvinas (ARVN) announced it will present first-in-human data from its Phase 1 study of ARV-102 at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) in Vienna, Austria, April 1-5, 2025.

The presentation will showcase data from both single-ascending and multiple-ascending dose portions of the study in healthy volunteers. ARV-102 is a PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a protein linked to Parkinson's disease and progressive supranuclear palsy.

The presentation, titled 'First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102,' is scheduled for April 4, 2025, at 3:20 p.m. CET during the LRRK2, Alpha-Synuclein, Parkin symposium session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary

Arvinas (ARVN) and Pfizer (PFE) announced positive topline results from their Phase 3 VERITAC-2 clinical trial for vepdegestrant, a first-in-class investigational oral PROTAC ER degrader for breast cancer treatment.

The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, showing statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population, though the trial did not reach statistical significance in the intent-to-treat population.

Vepdegestrant was generally well tolerated, with a safety profile consistent with previous studies. Overall survival data was not mature at analysis time, with less than 25% of required events occurred. The FDA granted Fast Track designation for vepdegestrant in February 2024 for monotherapy in ER+/HER2- advanced or metastatic breast cancer patients previously treated with endocrine-based therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-52.73%
Tags
-
Rhea-AI Summary

Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on targeted protein degradation, has announced its participation in three major investor conferences in March 2025:

  • Leerink Partners Global Healthcare Conference on March 11, featuring a fireside chat with CFO Andrew Saik and CBO Randy Teel, Ph.D.
  • Jefferies Biotech on the Beach Summit on March 12, where management will conduct one-on-one meetings
  • Barclays 27th Annual Global Healthcare Conference on March 13, including another fireside chat presentation

Live audio webcasts will be available for the Leerink and Barclays presentations through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
conferences
Rhea-AI Summary

Arvinas (ARVN) reported its Q4 and full year 2024 financial results with significant pipeline developments. The company anticipates topline data from the Phase 3 VERITAC-2 trial in Q1 2025. Phase 1b data from vepdegestrant combination therapy showed promising results with a 62.5% clinical benefit rate and 26.7% overall response rate.

Financial highlights include cash position of $1,039.4 million as of December 31, 2024, expected to fund operations into 2027. Revenue increased to $263.4 million for 2024, up from $78.5 million in 2023. R&D expenses decreased to $348.2 million from $379.7 million, while G&A expenses rose to $165.4 million from $100.3 million.

The company plans to initiate two new Phase 3 combination trials in 2025, including a first-line trial with Pfizer's atirmociclib and a second-line trial with a CDK4/6 inhibitor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
-
Rhea-AI Summary

Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced it will host a webcast to discuss its Q4 and full-year 2024 financial results. The presentation will take place on Tuesday, February 11, 2025, at 8:00 a.m. ET. Management will provide both financial results and a corporate update during the event. Investors can access the webcast through the company's website under the 'Events and Presentations' section, and a replay will be available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences earnings
-
Rhea-AI Summary

Arvinas (ARVN) announced key updates and milestones for 2025, focusing on its protein degradation drug pipeline. The company plans to initiate two Phase 3 combination trials for vepdegestrant in breast cancer treatment: a first-line trial combining with Pfizer's atirmociclib and a second-line trial with a CDK4/6 inhibitor, both starting in 2025.

Key upcoming milestones include: topline data from VERITAC-2 Phase 3 monotherapy trial in Q1 2025, initial data presentation from ARV-102 for Parkinson's disease, and preliminary results from ARV-393 Phase 1 trial in B-cell lymphomas. The company also plans to submit an IND for a PROTAC KRAS G12D degrader.

In corporate news, Alex Santini has been appointed interim Chief Commercial Officer, effective January 17, 2025, replacing John Northcott.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
Rhea-AI Summary

Arvinas (ARVN) and Pfizer (PFE) announced preliminary Phase 1b data from the TACTIVE-U sub-study evaluating vepdegestrant in combination with abemaciclib for breast cancer treatment. The study showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% in patients previously treated with CDK4/6 inhibitors.

The trial demonstrated a tolerable safety profile using abemaciclib 150mg twice daily with vepdegestrant 200mg once daily. No significant drug-drug interactions were observed. The most common side effects included diarrhea, nausea, and fatigue, with no grade 4 or 5 adverse events reported.

As of August 30, 2024, five patients remained on study treatment. The results support the ongoing Phase 2 portion of the study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
Arvinas

Nasdaq:ARVN

ARVN Rankings

ARVN Stock Data

591.44M
62.42M
7.62%
110.32%
18.47%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN